Drugs / BC3402
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05690425 | Jul 2023 → Mar 2024 | hematopoietic and lymphoid cell neoplasm | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05970822 | Jun 2023 → Mar 2025 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06608940 | Nov 2025 → Jan 2027 | hepatocellular carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06111326 | Oct 2023 → Aug 2024 | hepatocellular carcinoma | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC3402 | “BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous.” NCT06608940 ↗ |
| Action | Inhibit | “BC3402 is a TIM3 targeting inhibitory humanized IgG4 subtype monoclonal antibody” NCT06608940 ↗ |
| Modality | Monoclonal antibody | “BC3402 is a TIM3 targeting inhibitory humanized IgG4 subtype monoclonal antibody” NCT06608940 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT05690425 ↗ |